MultiOmic discovers and develops precision medicines for metabolic syndrome-derived diseases. The company uses deep longitudinal patient datasets, AI-enabled data science capabilities, and experimental biology expertise to identify patient subpopulations with distinct molecular-level disease drivers.

MultiOmic

Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). 

Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.

Verve Ventures

Ada Ventures

MMC Ventures

Hoxton Ventures

Selvedge Venture

OpenNano Pte. Ltd.

Pareto Holdings

Fifty Years

Formic Ventures

HOF Capital

Edward Lando

Jon Oringer

Nadav Ben-Chanoch

Multiomic Health

MultiOmic Health have some exciting news to share! Today, we are thrilled to announce our over-subscribed $6.2 million Seed Extension round, led by Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve Ventures.

This financing will enable us to take the next step in our journey to demonstrate proof-of-concept for our MOHSAIC platform in diabetic kidney disease, a condition with huge unmet medical need that now accounts for an estimated $300 billion annually in global healthcare costs.

We’d like to welcome all our new investors, and thank our existing investors for their ongoing support. Also, a huge shout out to the entire MultiOmic team, without whom none of this would have been possible.

Stay tuned for more updates on our progress and our continued commitment to advancing precision medicine for metabolic syndrome-related conditions.
#fundraising #investment #lifesciences #biotechnology #drugdiscovery #bioinformatics

We're thrilled to announce our participation at #BioEquityEurope 2024! 🚀 

🗓️ Save the date for May 14th at 14:20 CEST, where you can find us in Room 4+5 at the Kursaal Elkargunea Center, San Sebastián, Spain.

🌟 Robert Thong, our CEO at Multiomic Health, will be presenting on our innovative approach to tackle cardiorenal complications. Join us for insights into how we aim to transform the landscape of metabolic syndrome through precision medicine. 

🤝 We'd love to connect with you! Schedule a meeting with Robert or our COO, Celia Antonio Schell, and be sure to connect with us via the Bio€quity online partnering platform.

See you there!
#BioEquityEurope #PrecisionMedicine #MetabolicSyndrome #MultiOmicHealth

🌟 Exciting News Alert! 🌟

We're proud to announce our partnership with the Centre for Public Health at Queen's University Belfast (QUB) to revolutionise treatment for patients with diabetic kidney disease (DKD).

With the support of Innovate UK's Advancing Precision Medicine programme, we're leveraging insights from two world-class studies conducted by researchers at QUB and the Folkhälsan Research Centre.

Our goal is clear: to deliver more accurate diagnosis and treatment stratification for both type 1 and type 2 diabetes patients through the development of data-driven diagnostic tools.

Stay tuned for updates!

#MultiOmicHealth #QueensUniversityBelfast #Folkhälsan #NICOLA #FinnDiane #DiabeticKidneyDisease #Innovation #Collaboration

Andrew Parton Heather Jackson Rebecca Cripps Gareth McKay McKnight Amy Jayne, Prof Claire Hill, DPhil Laura Smyth Per-Henrik Groop Niina Sandholm Stefan Mutter

https://lnkd.in/dP8ivQhh

I'll be presenting Multiomic Health at the #BioEquityEurope conference week. Look forward to catching up with old friends and meeting new ones.

Proud to be selected as one of the top startups to pitch at Sifted tomorrow! 
Registration link to attend here: https://lnkd.in/euvP_jY4.

HEALTH:MULTIOMIC

MultiOmic

Analysis Not Available